This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information
DosingDosingDosing ScheduleDose ModificationsAboutAboutStudy MethodologyEfficacy & SafetyEfficacy & Safety Progression-free Survival & Objective Response RateCNS EfficacyGuidelinesSafety TablesSafety Overview

Menu

Close

DosingDosingDosing ScheduleDose ModificationsTherapy ManagementTherapy ManagementHyperlipidaemiaOedemaILD/PneumonitisCNS EffectsSummarySupport & ServicesSupport & ServicesSummary of Prescribing InformationDownloadable ResourcesEvents & WebinarsVideosUseful Links

LORBRIQUA® (lorlatinib) is indicated for the treatment of adult patients with ALK+ metastatic NSCLC.1

Brand A-Z
Scroll left to view table
Scroll left to view table
Scroll left to view table
Brand A-Z Brand A-Z
Scroll left to view table

Useful Links

If you are looking to find the latest cancer research or helpful support communities, here are some third-party resources to check out.

   

Information About Lung Cancer

Scroll left to view table

ALK Positive

ALK Positive is a worldwide community of patients, carers and supporters that provides information, empathy, support and research for those affected by ALK+ lung cancer.

 

  Learn more  Loading


GO2 Foundation for Lung Cancer
 

Two organisations serving the lung cancer community, the ALCF and the LCA, have proudly joined forces as the GO2 Foundation for Lung Cancer. They serve and advocate the needs of those impacted by or impacting the disease.
 

  Learn more  Loading


American Cancer Society
 

The American Cancer Society funds and conducts research, shares expert information and provides support for patients who have been affected by cancer.
 

  Learn more  Loading


Lung Cancer Foundation of America
 

The Lung Cancer Foundation of America aims to improve the survivorship of patients with lung cancer through the funding of transformative science.
 

  Learn more  Loading


Lung Cancer Research Foundation
 

The Lung Cancer Research Foundation focusses on lung cancer awareness and educational programmes, and funds research for the prevention, diagnosis, treatment and cure of lung cancer.
 

  Learn more  Loading


Lungcancer.org
 

Lungcancer.org was founded by CancerCare to be a source of support and information for patients with lung cancer and their loved ones.
 

  Learn more  Loading


LUNGevity.org
 

The LUNGevity Foundation is committed to making an immediate impact on increasing the quality of life and survivorship of people with lung cancer as well as to providing community, support and education for all those affected by the disease.
 

  Learn more  Loading


ALCF, Bonnie J. Addario Lung Cancer Foundation; ALK+, anaplastic lymphoma kinase-positive; LCA, Lung Cancer Alliance; NSCLC, non-small cell lung cancer.
​​​​​

Reference:

Lorbriqua. Local product document. Pfizer; 2021. Version LPDLOR082021.

   

Please click the Prescribing Information link to view the safety and adverse events information of LORBRIQUA®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.​​​​​​

   

PP-LOR-IND-0129 June 2022

Support & Services

Example

   

CNS Efficacy

82% IC response rate with LORBRIQUA® in patients with measurable brain metastases at baseline (BICR assessed)

Learn moreLoading

   

Efficacy & Safety


Learn moreLoading

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-LOR-IND-0129

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

 
Copyright © 2022 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • ​​​​​​​While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
 
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-UNP-IND-0012 July 2022
Yes No
You are now leaving PfizerPro website
​​​​​​​ ​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?

PP-UNP-IND-0012 July 2022


​​​​​​​